Novartis AG, of Basel, Switzerland, said its NVS Influenza Vaccines unit, now owned by Australia-based CSL Ltd., said the FDA's Vaccines and Related Biological Products Advisory Committee voted to recommend licensure of a candidate vaccine to help protect against seasonal influenza in people age 65 and older via accelerated approval.